1417646-41-3

Upstream product

• 1417646-19-5 C₃₀H₃₆N₂O₇ 
• 223718-30-7 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one 
• 118811-03-3 tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate 
• 1417646-37-7 4-((8-methyl-2-oxo-7-(2-(piperidin-2-yl)ethoxy)-2H-chromen-3-yl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate 
• 1417646-29-7 C₃₆H₄₄N₂O₈ 

Relevant academic research and scientific papers

COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS

Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for th

Novobiocin analogues with second-generation noviose surrogates

Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C-terminal inhibitor ever identified and recent structure-activity relationship studies on the noviose sugar identified several commercially available amines as suitable surrogates. In an effort to further understand this region of the molecule, analogues containing various N′-amino substituents were prepared and evaluated against two breast cancer cell lines for determination of their efficacy. Compound 37j manifested the most potent anti-proliferative activity from these studies and induced Hsp90-dependent client protein degradation at mid nano-molar concentrations.